Prakiraan wutah bathi saben saham kanggo taun ngarep IceCure Medical (ICCM)

Competition from chemotherapy and radiation therapy methods is creating pressure on IceCure Medical Ltd (ICCM). The projected net profit growth rate for n+1 illustrates the risks of model obsolescence, where the value of 32.10 characterizes this level. Stable demand for cryoablation ensures the macro-stability of the business. The company is currently focusing on expansion in the US, scaling sales of its nitrogen systems following FDA approval.

The global expansion of ProSense technology and FDA approvals are driving the future cash flows of IceCure Medical Ltd (ICCM). This indicator measures the expected earnings per share (EPS) dynamics, revealing the gap between expert forecasts and the actual scaling pace of B2B sales. By analyzing analysts' 12-month EPS growth targets, an investor can promptly identify the risks of missing objectives, which critically impacts the stability of the market capitalization.